Search research articles
Contact Us
Filters
Showing results (31-40 of 64) with videos related to
Page
of 7
Sort By:
British Journal of Clinical Pharmacology
|
May 29, 2014
Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model
Ivelina Gueorguieva, Ann L Cleverly, Anja Stauber, et al.
Drugs in Context
|
April 3, 2015
Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA
Allicia C Girvan, Gebra C Carter, Li Li, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 24, 2010
Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma
William G Herrington, Denis C Talbot, Michael M Lahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2009
Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer
A-R Hanauske, M Lahn, L C Musib, et al.
Cancer Chemotherapy and Pharmacology
|
September 5, 2019
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer
Ivelina Gueorguieva, Josep Tabernero, Davide Melisi, et al.
Oncology
|
September 1, 1997
Comparison of cytogenetics, cytokine secretion, and oncogene expression in primary cultures of renal carcinoma cells
M Lahn, R Kunzmann, G Köhler, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
April 1, 1997
Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts
A Mackensen, H Veelken, M Lahn, et al.
Drugs in Context
|
December 20, 2016
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, et al.
European Urology
|
February 6, 1999
Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma
M Lahn, P Fisch, G Köhler, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 30, 1998
Early preferential stimulation of gamma delta T cells by TNF-alpha
M Lahn, H Kalataradi, P Mittelstadt, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 64) with videos related to
Sort By:
Page
of 7
British Journal of Clinical Pharmacology
|
May 29, 2014
Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model
Ivelina Gueorguieva, Ann L Cleverly, Anja Stauber, et al.
Drugs in Context
|
April 3, 2015
Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA
Allicia C Girvan, Gebra C Carter, Li Li, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 24, 2010
Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma
William G Herrington, Denis C Talbot, Michael M Lahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2009
Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer
A-R Hanauske, M Lahn, L C Musib, et al.
Cancer Chemotherapy and Pharmacology
|
September 5, 2019
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer
Ivelina Gueorguieva, Josep Tabernero, Davide Melisi, et al.
Oncology
|
September 1, 1997
Comparison of cytogenetics, cytokine secretion, and oncogene expression in primary cultures of renal carcinoma cells
M Lahn, R Kunzmann, G Köhler, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
April 1, 1997
Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts
A Mackensen, H Veelken, M Lahn, et al.
Drugs in Context
|
December 20, 2016
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, et al.
European Urology
|
February 6, 1999
Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma
M Lahn, P Fisch, G Köhler, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 30, 1998
Early preferential stimulation of gamma delta T cells by TNF-alpha
M Lahn, H Kalataradi, P Mittelstadt, et al.
Page
of 7